British pharma titan GlaxoSmithKline is building on research carried out by Rockville,Maryland biotech firm Human Genome Sciences.Two of GSK's pipeline projects are based on HGS technology.
Darapladib is an inhibitor of the Lp-PLA2 enzyme,which is believed to be a risk factor for coronary heart disease and ischemic stroke.It is a potentially important new treatment for prevention of cardiovascular events.The candidate drug discovered by GSK using an HGS technology is in a Phase 3 trial for efficacy and safety of treatment.
Albiglutide is a biological product created by HGS and licensed by GSK IN 2004.It is designed to act throughout the body to help maintain blood glucose levels and control appetite.This potential long term treatment for type 2 diabetes is also in a Phase 3 trial.
HGS has a substantial financial interest in both of these GSK products which its research has had a formative influence on.
GlaxoSmithKline and Human Genome Sciences are also co-owners and developers of Benlysta,the first new lupus treatment approved in the U.S. in 50 years.
GlaxoSmithKline(GSK),Human Genome Sciences(HGSI)
No comments:
Post a Comment